Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 213.75M P/E - EPS this Y 53.30% Ern Qtrly Grth -
Income -72.5M Forward P/E -2.52 EPS next Y -3.30% 50D Avg Chg -27.00%
Sales 20.71M PEG - EPS past 5Y - 200D Avg Chg -37.00%
Dividend N/A Price/Book 2.48 EPS next 5Y - 52W High Chg -66.00%
Recommedations 1.50 Quick Ratio 2.81 Shares Outstanding 41.55M 52W Low Chg 93.00%
Insider Own 28.68% ROA -49.37% Shares Float 22.51M Beta -
Inst Own 33.82% ROE -216.21% Shares Shorted/Prior 1.13M/1.12M Price 5.31
Gross Margin -246.38% Profit Margin - Avg. Volume 348,912 Target Price 7.60
Oper. Margin -126.89% Earnings Date Nov 7 Volume 130,613 Change -5.68%
About Carisma Therapeutics, Inc.

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Carisma Therapeutics, Inc. News
11/17/24 Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
11/08/24 Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
11/07/24 Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/05/24 Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
10/30/24 Carisma Therapeutics Announces Changes to its Board of Directors
10/04/24 Carisma Therapeutics Announces Upcoming Presentations at SITC 2024
09/10/24 Carisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases
09/10/24 Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
09/03/24 Carisma Therapeutics to Present at Upcoming Conferences
08/13/24 CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?
08/08/24 Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
08/08/24 Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
08/06/24 Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board
08/06/24 Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024
08/03/24 Can Carisma Therapeutics (NASDAQ:CARM) Afford To Invest In Growth?
06/27/24 Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
06/26/24 Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
06/25/24 Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
06/25/24 Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
06/13/24 Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
CARM Chatroom

User Image sorencyrus Posted - 3 hours ago

$CARM Fintel updated price target from $7.60 to $10.61

User Image TradesBB Posted - 3 hours ago

$CARM RFK JR is telling some of the corrupt people at the FDA to pack their bags. Now time for foots up rears for screwing us over at sesn lol

User Image jmarz9 Posted - 1 day ago

$CARM This may be a pipe dream but I’d love to see an investigation on to why Vicinium didn’t get approved. And if Merck had any to do with it (Ketruda). FDA is going to get a well needed overhaul. I’m hoping. Companies in business for over 100 years and not one cure!!! More Money to treat the ailments. Yup. 👍

User Image Williamstock70 Posted - 1 day ago

$TNXP lots of interest, high volume, let's go! There are other penny stocks that are waking up, for example $QSI , $SLXN,..... watch out for rising volume in $VVPR and $CARM and BLIN , could be next. They are giving signals. 🔥👀

User Image clostov1919 Posted - 1 day ago

$CARM Where is Vicineum/Durvalumab!

User Image CBARRR8 Posted - 1 day ago

$CARM Can't wait till 8 cents.

User Image fuego Posted - 1 day ago

$CARM I've been long since SESN merger. It seems concerns about operating cash are overshadowing any positive news we get. Moderna will likely determine CARM's future. What does that look like and how long will it take?

User Image steven1x Posted - 2 days ago

$CARM if missed https://carismatx.com/wp-content/uploads/2024/11/Final-Version-1-111824-AASLD_2024_Fibrosis.pdf

User Image DiamondDog32 Posted - 3 days ago

$CARM THIS WILL REVERSE 1 /5 1/10 1/20 eventually.. SESEN GARBAGE .. Nice tommy boy ... Vici by way of the DO DO bird.. as TOROK flies away

User Image Trending__Now Posted - 3 days ago

$CARM Out of CARM. Carm needs Moderna to provide IND and milestone. I don't want to leave but this dependency on Moderna is too much of a risk when there's other choices. Once again take a look at AUTL and CARP. Both have 2X potential next 6 months. Good luck if you're staying in CARM.

User Image Williamstock70 Posted - 3 days ago

$CARM Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 Nov 17, 2024 https://ir.carismatx.com/news-releases/news-release-details/carisma-therapeutics-presents-promising-new-preclinical-data

User Image TradesBB Posted - 3 days ago

$CARM RFK Jr is going to get rid of the corruption in the fda. This should be good news. Sesn needs some retribution here

User Image fuego Posted - 6 days ago

$CARM CARM says to SESN, 'hold my beer, i got this'

User Image TradesBB Posted - 6 days ago

$CARM How much cash is on hand right now. Do people think there will be an RS here. Only people who are not constantly bashing here can respond. We know who thinks there will be one. I'm thinking about adding more at these levels soon

User Image DiamondDog32 Posted - 6 days ago

$CARM RIGHT BACK TO FULL ROUND TRIP SESEN 60s

User Image fuego Posted - 6 days ago

$CARM at 93 cents still no buyers, inside or outside. Spooky.

User Image TradesBB Posted - 1 week ago

$CARM Where's that CVR

User Image fuego Posted - 1 week ago

$CARM shorts won't cover til we get a strong catalyst.

User Image TradesBB Posted - 1 week ago

$CARM Whats with the we gotta hold this under 1 constantly here

User Image builderup Posted - 1 week ago

New positions (Swing) $NRXP $CARM $VANI Keep these on your radar!

User Image hall1809 Posted - 1 week ago

$CARM after Merk sabotaged Vici with former scam artist hit piece article! Big Pharma owns the FDA hopefully shet changes with RFK cleaning house… We need to get data to someone in his branch once smoke clears… While maybe zero chance still a chance for all large CVR holders..

User Image clostov1919 Posted - 1 week ago

$CARM Where is Vicinium

User Image hall1809 Posted - 1 week ago

$CARM the FDA big Pharma corrupt as RFK knows Vici needs to be brought to his attention once FDA gets gutted! Have until 2027 so time not an issue

User Image UtahLife14 Posted - 1 week ago

$CARM Vicineum/Durvalumab!

User Image Flexed1ga Posted - 1 week ago

$CARM SESN two the Movie

User Image StockFlips Posted - 1 week ago

Gainers last week: Part 1 $AMIX $ELWS $CARM $ALBT

User Image Trending__Now Posted - 1 week ago

$CARM The IND submission to the FDA is expected soon. The FDA generally takes 30 days to review, so approval could come before the end of the year. If approved, Carisma and Moderna might begin a Phase 1 trial (or similar) in Q1 2025, and at the latest, by the second half of 2025. Preliminary results could start to emerge about 60 days following the trial's initiation. The combination of anti-GPC3 CAR mRNA/LNP with Pembrolizumab could be the knockout for some tumors. IND next 2 weeks?

User Image petite Posted - 1 week ago

$CARM Will it ever go up?

User Image underdog531 Posted - 1 week ago

$CARM I hope the analysts are correct about the $24 price target and this price is not reflective of a reverse split? Anyway they have great news and I'm looking forward to more positive feedback regarding their pipeline.

User Image fuego Posted - 1 week ago

$CARM Great news. This is part of the Moderna collaboration, right? Bought some more CARM this AM. Cash is tight, but the product is right.

Analyst Ratings
HC Wainwright & Co. Buy Jun 28, 24
HC Wainwright & Co. Buy Jun 26, 24
HC Wainwright & Co. Buy May 17, 24
HC Wainwright & Co. Buy May 10, 24
BTIG Buy Apr 11, 24
HC Wainwright & Co. Buy Apr 2, 24
HC Wainwright & Co. Buy Nov 29, 23
Capital One Overweight Oct 3, 23
HC Wainwright & Co. Buy Sep 6, 23